LUNG TRANSPLANTATION

Bronchiolitis obliterans following lung transplantation: early detection using computed tomographic scanning

P A de Jong, J D Dodd, H O Coxson, C Storness-Bliss, P D Paré, J R Mayo, R D Levy

Thorax 2006;**61**:799–804. doi: 10.1136/thx.2005.053249

See end of article for authors' affiliations

Correspondence to: Dr R D Levy, BC Transplant Society, 3rd Floor, West Tower, 555 West 12th Avenue, Vancouver, BC, Canada V5Z 3X7; rlevy@providencehealth.bc.ca

Received 3 October 2005
Accepted 21 April 2006
Published Online First 2 May 2006

Background: Computed tomographic (CT) scanning may enable earlier diagnosis of chronic lung allograft dysfunction than forced expiratory volume in 1 second (FEV_1). A study was undertaken to determine intra-observer and inter-observer agreement of composite and air trapping CT scores, to examine the association of FEV_1 with the composite and air trapping CT score, and to relate the baseline composite CT score to changes in FEV_1 and changes in the composite CT score over 1 year.

Methods: Lung function and baseline CT scans following transplantation and at subsequent annual follow ups were analysed in 38 lung transplant recipients. Scans were randomly scored by two observers for bronchiectasis, mucus plugging, airway wall thickening, consolidation, mosaic pattern, and air trapping, and re-scored after 1 month. CT scores were expressed on a scale of 0–100 and correlated with FEV_1 as a percentage of the post-transplant baseline value.

Results: The mean (SD) interval between baseline and follow up CT scans was 11.2 (4.7) months. Inter-observer and intra-observer agreement was good for both the composite and air trapping CT scores. There was a significant association between FEV_1 and the composite CT score, with each unit of worsening in the baseline composite CT score predicting a 1.55% and 1.37% worsening in FEV_1 over the following year ($p<0.0001$) and a 1.25 and 1.12 unit worsening in the composite CT score ($p<0.0001$) for observers 1 and 2, respectively.

Conclusion: These findings indicate a potential role for a composite CT scoring system in the early detection of bronchiolitis obliterans.

Long term survival after lung transplantation is limited by the development of chronic allograft dysfunction which manifests as bronchiolitis obliterans (BO). BO consists of heterogeneously distributed areas of obliterated respiratory and terminal bronchioles that lead ultimately to a decline in forced expiratory volume in 1 second (FEV_1), graft failure and recipient death.[1–4] It is thought that earlier diagnosis and more timely treatment of BO could improve long term survival;[1–3 5 6] however, the heterogeneous distribution of BO within the transplanted lungs renders invasive diagnosis by transbronchial biopsy unreliable, with reported sensitivities as low as 17–28%.[3 7 8] In an attempt to identify BO earlier, a functional surrogate for this structural abnormality—bronchiolitis obliterans syndrome (BOS)—has been defined as a progressive decline in FEV_1.[9] Unfortunately, identifying patients using BOS criteria still may not identify subjects early enough in the development of airflow limitation due to the distribution of the BO process. Investigators have recently turned their attention to computed tomographic (CT) scoring systems because it is thought that direct evaluation of anatomical markers may allow earlier detection of BO than indirect measurements such as FEV_1.

There are, however, limitations to CT scoring systems, predominately due to sensitivity and specificity for disease progression as well as the high inter-observer and intra-observer variability of the score itself. For example, it has been suggested that air trapping is the most sensitive and specific CT abnormality for the early detection of BOS[10–14] while exhibiting the highest inter-observer agreement.[14–16] However, more recent work has not always confirmed these findings[17] and there is no consensus on how to score air trapping. For example, Bankier *et al* evaluate gas trapping as 0–20%, 20–40%, 40–60%, 60–80% or 80–100% of the lobe involved,[14 16] while Siegel *et al* score the lobes as 0%, 1–25%, 26–50%, 51–75%, and 76–100%.[13] Furthermore, scores for mosaic pattern of attenuation, airway wall thickening, and bronchiectasis are individually less sensitive and specific than scores for air trapping,[10–14 17] and the intra- and inter-observer agreement individual scores for bronchiectasis, airway wall thickening, and mosaic pattern have not been evaluated in lung transplant recipients. Therefore, given the variety of CT abnormalities seen in BO/BOS, it may be that a composite CT score (CT_{BO} score) will be more sensitive and specific than a CT air trapping score (CT_{AT} score) alone for the early detection of BO.

The aims of the present study were (1) to determine the intra- and inter-observer agreement of a CT_{BO} score and a CT_{AT} score, (2) to determine the cross sectional relationship between the CT_{BO} score and CT_{AT} score with FEV_1, and (3) to relate the CT_{BO} score at baseline to changes in FEV_1 and changes in the CT_{BO} score over the course of 1 year. Our hypotheses were that (1) the CT_{BO} and CT_{AT} scores would show significant associations with FEV_1 in lung transplant recipients and (2) the CT_{BO} score at baseline would predict changes in FEV_1 and changes in the CT_{BO} score over the course of 1 year.

METHODS

Subjects

The baseline CT scan (first scan following transplantation) and the first annual surveillance CT (follow up) scan of 38 consecutive subjects who received a single or double lung

Abbreviations: BO, bronchiolitis obliterans; BOS, bronchiolitis obliterans syndrome; CT, computed tomography; FEV_1, forced expiratory volume in 1 second

transplant at our centre since 2000 were studied. CT scans were excluded when performed for the diagnosis of acute clinical events, when there were incidental CT findings of acute disease (such as pneumonia), or when the recipient had coincident clinical or bronchoscopic evidence of an acute event (acute rejection, infection). We did not routinely perform bronchial provocation testing on our lung transplant recipients. None of the subjects included in the study had clinical manifestations of asthma after transplantation and none had significant bronchodilator responses according to ATS criteria on spirometry. The study was approved by the clinical ethics review board of the University of British Columbia.

CT scans

All CT scans were performed on a GE Lightspeed Ultra scanner (General Electric Medical System, Milwaukee, WI, USA). Inspiratory images were acquired at suspended inspiration from lung apex to base using 1.25 mm slice thickness at 10 mm intervals. Expiratory 1.25 mm thick images were acquired at end of exhalation at the level of the aortic arch, the carina and 2 cm above the hemidiaphram. Images were acquired using 150 mA, 120 kVp, 1 second scan time, reconstructed using a high spatial frequency algorithm (''Bone'') and an appropriate field of view. For the first part of the study each baseline CT scan was assigned a random identification number, blinded for patient characteristics and reviewed using a medical imaging workstation (Leonardo Workstation, Siemens AG Medical Solutions, Erlangen, Germany). For the second part of the study each pair of baseline plus follow up scans was assigned another random identification number, blinded for patient characteristics and reviewed as per baseline.

Spirometric tests

Spirometric tests were performed according to ATS guidelines.[18] For the purposes of this study, FEV_1 was expressed as a percentage of the average of the two best FEV_1 values obtained after lung transplantation.[9] BOS was defined according to the International Society of Heart and Lung Transplantion guidelines with BOS stage 0 as FEV_1 >80% post-transplant baseline value and stages 1, 2 and 3 equivalent to FEV_1 66–80%, 51–65%, and <50% post-transplant baseline, respectively.[9]

CT scoring

To establish the CT scoring system, two observers (PAJ, JDD) independently scored the baseline CT scans in a random and blinded fashion. To test for intra-observer variation, one observer re-scored all baseline CT scans after 1 month.

Our CT scoring system is presented in table 1 and illustrative examples are shown in fig 1. The CT scans were viewed using display settings of window, −500 Hounsfield Units (HU) and level, 1500 HU. Inspiratory scans were evaluated for severity and extent of central and peripheral bronchiectasis; extent of central and peripheral mucus plugging; severity and extent of central and peripheral airway wall thickening; extent of consolidation; and extent of mosaic pattern. Expiratory scans were evaluated for the extent of air trapping. Each of the five lobes (including the lingula as a sixth ''lobe'') was evaluated separately using the inspiratory CT image while six lung zones (upper, middle, lower left and right) were scored using the expiratory images. In single lung transplant recipients, only the lobes of the transplanted lung were scored.

Abnormalities were defined according to recommendations of the nomenclature committee of the Fleischner Society. To score peripheral bronchiectasis and airway wall thickening, ''peripheral'' was defined as less than 2 cm from the costal and diaphragmatic pleura. Visible airways abutting the mediastinal pleura were scored as bronchiectasis. Peripheral mucus plugging was evaluated using the radiological appearance of ''centrilobular nodules'' or ''tree-in-bud'' pattern rather than using a peripheral location. Central mucus plugging was scored if mucus was seen in identifiable bronchi. Mild airway wall thickening was defined as an airway wall thickness greater than 2 mm in the hilum, 1 mm in the central, and 0.5 mm in the peripheral lung. Mild bronchiectasis was defined as a bronchial lumen diameter greater than the diameter of the adjacent pulmonary artery or as a lack of tapering between bronchial generations.

Scores for bronchiectasis, mucus plugging, airway wall thickening, air trapping, and a composite CT_{BO} score were calculated in a similar manner to Brody *et al*.[19] In brief, for each lobe a bronchiectasis score, mucus plugging score, and airway wall thickening score were calculated by combining the abnormalities and severity of the abnormalities in the central and peripheral lung. Next, the lobe scores for bronchiectasis, mucus plugging, airway wall thickening, consolidation, mosaic pattern, and air trapping were summed to produce a total maximum of 108, 54, 36, 18, 18 and 18, respectively. The composite score was calculated by adding the component scores together for a total maximum of 252. The maximum total scores and maximum component scores were expressed on a scale of 0–100 for statistical analysis.

For the second part of the study, after 3 months the baseline CT scans were combined with the follow up CT scans, randomised, and scored using the above scoring system to assess the predictive value of the scoring system for disease progression. The readers did not have information as to which were baseline scans and which were follow up scans. The scores from this reading were also used to evaluate the intra-observer agreement.

Statistical analysis

Intra-observer and inter-observer agreement of scores for CT components, CT_{AT} score, and CT_{BO} score were calculated using intraclass correlation coefficients. An intraclass correlation coefficient of more than 0.8 represents good agreement.

Linear regression was used to model the association between CT score and FEV_1 measured at baseline. The regression analysis was conducted for the CT_{BO} score and the CT_{AT} score and for each observer separately. The regression coefficient was a measure of association, showing the mean decrease in CT score for every additional percentage change in FEV_1. The analysis was repeated for follow up measurements and was conducted for observers 1 and 2 separately. The linear regression was also used to model the association between the baseline CT_{BO} score and FEV_1 at follow up and the baseline CT_{BO} score and CT_{BO} score at follow up. Finally, the linear regression was used to model the association between the baseline CT_{AT} score and FEV_1 at follow up and the baseline CT_{AT} score and CT_{AT} score at follow up. The analysis was conducted for observers 1 and 2 separately.

A p value of <0.05 was considered significant and all data are presented as mean (SD, range) unless indicated otherwise.

RESULTS

Study population

The mean age at transplantation of the 38 lung transplant recipients included in the study was 43.7 (SD 13.1, range 12.7–64.6) years. The interval between transplantation and baseline CT scans was 44 (SD 33, range 2–120) months and the interval between baseline and follow up CT scans was 11.2 (SD 4.7, range 2.3–17.4) months. At the time of the baseline CT scan, 22, 10, 4 and 2 patients were in BOS stages



Figure 1 Representative CT images showing the CT_{BO} scoring system abnormalities. A collection of transaxial 1.25 mm CT sections in different patients viewed at lung window and level setting (width 1500 HU, level −500 HU) showing (A) bronchiectasis (arrows) identified by the absence of normal bronchial diameter tapering; (B) peripheral mucus plugging shown as multiple centrilobular nodules (arrows); (C) dilated bronchus with associated wall thickening (arrow); (D) lingular consolidation (arrow) shown as an area of increased density obscuring the underlying pulmonary vasculature; (E) generalised mosaic pattern in both upper lobes shown by areas of decreased attenuation and vessel size (straight arrow) compared with regions of normal attenuation and normal vessel size (curved arrow); and (F) expiratory image showing areas of air trapping (arrows).

0, 1, 2 and 3, respectively, by spirometric criteria. One patient did not have a follow up CT scan and another was excluded from follow up analysis because of biopsy proven acute rejection. Other subject characteristics are given in table 2.

Inter- and intra-observer agreement

The inter-observer and intra-observer agreement for the CT_{AT} score, CT_{BO} score, and other component scores are shown in table 3. An intraclass correlation coefficient above 0.80 was

Table 1 CT_{BO} scoring system for one lobe*

CT abnormality	Score 0	1	2	3
Bronchiectasis				
Central lung (extent)	Absent	<33%	33–67%	>67%
Peripheral lung (extent)	Absent	<33%	33–67%	>67%
Size of largest	Absent	B <2 V	B 2–3 V	B >3 V
Size of average	Absent	B <2 V	B 2–3 V	B >3 V
Mucus plugging				
Central (extent)	Absent	<33%	33–67%	>67%
Peripheral (extent)	Absent	<33%	33–67%	>67%
Airway wall thickening				
Severity	Absent	Mild	0.5–1 V	>1 V
Central lung (extent)	Absent	<33%	33–67%	>67%
Peripheral lung (extent)	Absent	<33%	33–67%	>67%
Consolidation (extent)	Absent	<33%	33–67%	>67%
Mosaic pattern (extent): inspiratory CT scan finding	Absent	<33%	33–67%	>67%
Air trapping (extent): expiratory CT scan finding	Absent	<33%	33–67%	>67%

Bronchiectasis: peripheral is 1–2 cm from the costal/diaphragmatic pleura or abutting the mediastinal pleura; B, diameter of bronchial lumen; V, diameter of accompanying pulmonary artery.
Mucus plugging: central = plugging in identifiable bronchi; peripheral = centrilobular nodules and tree in bud.
Airway wall thickening: mild = >2 mm in hilum, 1 mm centrally and 0.5 mm peripherally.
*Scores for each abnormality were calculated according to Brody *et al*.[19] Figure 1 shows images corresponding to the scoring system abnormalities.

Table 2 Characteristics of study population

Type of transplantation	
Single lung (n)	21
Double lung (n)	16
Heart lung (n)	1
Diagnosis	
Cystic fibrosis (n)	13
Emphysema/COPD (n)	11
AAT, IPF and LAM (n)	3 each
PAH, idiopathic obliterative bronchiolitis (n)	2 each
Langerhans cell histiocytosis, sarcoidosis (n)	1 each
Spirometry	
FEV_1 at baseline CT (% baseline post-transplant)	82 (18, 34–100)
FEV_1 at follow up CT (% baseline post-transplant)	77 (21, 27–100)
CT scores	
CT_{AT} score at baseline CT (unit)	47 (23, 0–100)
CT_{AT} score at follow up CT (unit)	51 (23, 0–100)
CT_{BO} score at baseline CT (unit)	7 (4, 1–16)
CT_{BO} score at follow up CT (unit)	7 (5, 0–24)

Values are mean (SD, range) or absolute numbers.
CT data are given for observer 1.
COPD, chronic obstructive pulmonary disease; AAT, α_1-antitrypsin deficiency; IPF, idiopathic pulmonary fibrosis; LAM, lymphangioleiomyomatosis; PPH, pulmonary arterial hypertension; CT, computed tomography; AT, air trapping; BO, bronchiolitis obliterans; FEV_1, forced expiratory volume in 1 second.

considered to represent good agreement. The inter-observer agreement was above 0.80 for the CT_{AT} score and the bronchiectasis CT score. However the CT_{BO} score and consolidation, mucus plugging, airway wall thickening, and mosaic pattern component scores were below 0.80. The intra-observer agreement after 1 month was good for the CT_{AT} score and the CT_{BO} score but was below 0.80 for mucus plugging, airway wall thickening, and mosaic pattern component scores (table 3).

Relationship between baseline FEV_1 and CT_{BO} score or CT_{AT} score

There was a significant association between FEV_1 and both the CT_{BO} score and the CT_{AT} score measured at baseline (fig 2), with a higher (more damage) CT score corresponding to a lower (worse) FEV_1 value. The baseline CT_{BO} score increased by 0.20 ($p = 0.0001$, observer 1) and 0.26 ($p<0.0001$, observer 2) and the baseline CT_{AT} score increased by 0.55 ($p = 0.02$, observer 1) and 0.55 ($p = 0.02$, observer 2) for each percentage decrease in baseline FEV_1 (fig 2). The follow up CT_{BO} score increased by 0.25 ($p<0.0001$, observer 1) and 0.27 ($p<0.0001$, observer 2) and the follow up CT_{AT} score increased by 0.36 ($p = 0.002$, observer 1) and 0.63 ($p<0.0001$, observer 2) for each percentage decrease in follow up FEV_1.

We divided the subjects into a group without BOS (FEV_1 >80% baseline) and a group with BOS (FEV_1 <80% baseline) and arbitrarily set a CT score of >5 as abnormal. In patients without BOS, 12 of 22 had a CT score >5 (55% of patients with normal FEV_1 had an abnormal CT score). Air trapping alone was present in 19 of the 22 subjects without BOS (86%). In subjects with BOS, 13 of 16 had an abnormal CT score >5 (81%) and air trapping alone was present in 16 (100%).

Relationship between baseline CT_{BO} score and changes in CT_{BO} score and FEV_1

There were significant associations between the baseline CT_{BO} score and both FEV_1 and the CT_{BO} score measured after 1 year. The mean FEV_1 at follow up decreased by 1.55% (observer 1) or 1.37% (observer 2) of baseline for every additional unit in the CT_{BO} score at baseline ($p<0.0001$). The mean CT_{BO} score at follow up increased by 1.25 units (observer 1) or 1.12 units (observer 2) for every additional unit in the CT_{BO} score at baseline ($p<0.0001$).

Table 3 Intra-observer and inter-observer agreement of CT abnormalities including air trapping and composite CT_{BO} score

	Inter-observer agreement	Intra-observer agreement
CT_{AT} score	0.86	0.97
CT_{BO} score	0.78	0.94
Bronchiectasis score	0.84	0.94
Consolidation score	0.78	0.90
Mosaic pattern score	0.68	0.72
Airway wall thickening score	0.61	0.72
Mucus plugging score	0.12	0.39

Data are intraclass correlation coefficients. An intraclass correlation coefficient of greater than 0.8 represents good intra-observer and inter-observer agreement.
CT, computed tomography; AT, air (gas) trapping; BO, bronchiolitis obliterans.

Relationship between baseline CT_{AT} score and changes in CT_{AT} score and FEV_1

There were significant associations between the baseline CT_{AT} score and both FEV_1 and the CT_{AT} score measured after 1 year. The mean FEV_1 at follow up decreased by 0.27% (observer 1) or 0.24% (observer 2) of baseline for every additional unit in the CT_{BO} score at baseline ($p = 0.0003$ and $p = 0.0004$, respectively). The mean CT_{BO} score at follow up increased by 0.74 units (observer 1) or 0.68 units (observer 2) for every additional unit in the CT_{BO} score at baseline (both $p<0.0001$).

DISCUSSION

The aims of the present study were to determine the intra- and inter-observer agreement of the CT_{BO} score and CT_{AT}



Figure 2 Association between FEV_1 at baseline CT scan and (A) bronchiolitis obliterans (CT_{BO}) score and (B) air trapping (CT_{AT}) score at baseline CT scan. The CT_{AT} score showed a greater and stronger association than the CT_{BO} score (slope 0.55 for CT_{AT} score versus 0.20 for CT_{BO} score), but the association of the CT_{AT} score with FEV_1 appeared to be less precise than for the CT_{BO} score ($p = 0.02$ and $p = 0.0001$, respectively). Data given are for observer 1 first observation.

score, to determine the cross sectional association between the CT_{BO} score and CT_{AT} score with FEV_1, and to relate the CT_{BO} score at baseline to changes in FEV_1 and changes in the CT_{BO} score over the course of 1 year. Our hypotheses were that (1) the CT_{BO} score and CT_{AT} score would show significant associations with FEV_1 and (2) the CT_{BO} score at baseline would predict changes in FEV_1 and the CT_{BO} score over the course of 1 year. This study was not designed to determine if the CT_{BO} score is more useful than the CT_{AT} score.

Similar to previous studies,[14 16] our data show good inter-observer and intra-observer agreements for the CT_{AT} score. However, also similar to a previous study,[13] the intraclass correlation coefficient for the composite CT_{BO} score in our study was borderline. This was related to the relatively low level of inter-observer agreement in scoring mucus plugging, airway wall thickening, and mosaic pattern. A number of factors may be responsible for the disagreements in scoring airway wall thickening and mosaic pattern. Firstly, most of our patients had mild (BOS-0 and BOS-1) airflow obstruction. As the CT scans showed only subtle abnormalities, this makes scoring more difficult than in cystic fibrosis where the abnormalities are more pronounced, although in cystic fibrosis studies the scores for airway wall thickening and mosaic pattern were also not very reproducible.[15 20] Secondly, although both observers had substantial expertise with interpretation and scoring of chest CT scans, they had limited experience of reading CT scans from lung transplant recipients. However, this situation may accurately reflect the typical clinical setting where chest CT scans are often read by radiologists with limited experience in lung transplant CT interpretation. Inter-observer agreement may be better for observers in large transplant centres who are more experienced in evaluating CT scans of lung transplant recipients. Alternatively, it may be best to combine these subjective scoring systems with a computerised analysis of lung parenchyma[21 22] and airways[23 24] which could combine the clinical impression with objective quantitative values.

The most important findings of this study are that both the CT_{BO} and CT_{AT} scores are significantly associated with FEV_1, and both scores predicted the clinical course of a patient over the year following the CT scan. A 1% higher CT_{BO} score at baseline predicts a 1.55% faster worsening in FEV_1 and a 1.25% faster worsening in the CT_{BO} score over the coming year (observer 1). Similarly, a 1% higher CT_{AT} score at baseline predicts a 0.27% faster worsening in FEV_1 and a 0.74% faster worsening in the CT_{BO} score over the coming year (observer 1). This finding suggests that both the composite CT_{BO} score and the CT_{AT} score could potentially identify BO earlier than FEV_1. We cannot determine from our study whether the CT_{BO} score is more useful than the CT_{AT} score, and it would therefore be prudent for future longitudinal studies evaluating the usefulness of subjective CT interpretation in BO to include a composite CT score as well as an air trapping CT score alone.

Nevertheless, these results support the concept that CT scanning is a valuable tool in the evaluation and follow up of lung transplant recipients. Lung function is currently the ''gold standard'' for detecting lung allograft dysfunction, but it is an indirect measurement and can only give a global assessment of the pulmonary condition. The major advantage of CT scanning is that it is a direct measure of lung structure and allows for the identification of structural abnormalities associated with chronic allograft dysfunction, including bronchiectasis, airway wall thickening, mucus in small and large airways, and air trapping due to small airway abnormalities. Furthermore, CT imaging allows for the detailed analysis of the regional distribution of pathological processes such as BO. This is particularly pertinent in single lung transplant recipients in whom physiological measures such as FEV_1 are confounded by the contribution from the native lung. Even in double lung transplant recipients, lung function tests may be insensitive in those with a heterogeneous distribution of damage, especially when the abnormalities are located in the most peripheral airways. For these reasons, we suggest that CT scanning could identify BO earlier than FEV_1, at a time when changes in immunosuppression may result in improved clinical outcomes. The use of clearly defined CT parameters (particularly a composite CT score that quantifies numerous lung components), possibly in combination with quantitative CT measures, may therefore have an important role as a standardised outcome for research trials involving BO.

In this study we did not analyse our data using the BOS 0-p stage. Because FEV_1 declines later in the disease process, this new category (BOS 0-p) was added based on forced expiratory flows between 25% and 75% of forced vital capacity ($FEF_{25–75}$).[3] However, its prognostic usefulness has been debated,[17 25] with variable positive and negative predictive values reported. In view of this uncertainty, our statistical analysis was performed using FEV_1 as a continuous variable rather than being based on BOS stages, and hence this did not affect our analysis.

Potential limitations of the study include the relatively small study population, the short follow up, and the variation in timing of the baseline CT scan. A larger number of patients followed over a longer time frame would be useful to help characterise the potential role of CT scans for the early detection of chronic lung allograft dysfunction. Such a study could also examine the optimal interval between CT scans to detect BO earlier than FEV_1. Finally, our analysis may be limited by the fact that only three expiratory CT images were obtained and it may be advantageous in future studies to increase this number.

In conclusion, we systematically evaluated inter-observer and intra-observer agreement for qualitative CT scoring of a variety of abnormalities including a composite CT_{BO} score in a patient population with predominantly mild abnormalities. Both the composite CT_{BO} score and the CT_{AT} score had good or fairly good inter-observer and intra-observer agreement. Our findings indicate a potential role for a composite CT score, as well as an air trapping score alone, in lung transplant recipients.

ACKNOWLEDGEMENTS

The authors acknowledge Dr Boris Sobolev for his statistical advice, the British Columbia Lung Association and the Canadian Institute of Health Research/Michael Smith Foundation for financial support, and the staff of the British Columbia Transplant Society Lung Transplant Program for help with the collection of data.

Authors' affiliations
P A de Jong, C Storness-Bliss, P D Paré, R D Levy, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
P A de Jong, J D Dodd, H O Coxson, C Storness-Bliss, J R Mayo, Department of Radiology, University of British Columbia, Vancouver, BC, Canada
P A de Jong, Department of Radiology, Meander Medical Center, Amersfoort, the Netherlands
P A de Jong, H O Coxson, P D Paré, R D Levy, James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, Vancouver, BC, Canada
P A de Jong, R D Levy, British Columbia Transplant Society, Vancouver, BC, Canada

Dr de Jong was supported by a British Columbia Lung Association Fellowship in Respiratory Medicine and a Canadian Institute of Health Research/Michael Smith Foundation Transplant Research Training Award and Dr Coxson is a Parker B Francis Fellow in Pulmonary Research.

Conflict of interest: The authors declare no competing interest in the content of this manuscript.

REFERENCES

1 **Trulock EP**, Edwards LB, Taylor DO, *et al*. The registry of the International Society for Heart and Lung Transplantation: 21st official adult heart transplant report—2004. *J Heart Lung Transplant* 2004;**23**:804–15.
2 **Boehler A**, Estenne M. Post-transplant bronchiolitis obliterans. *Eur Respir J* 2003;**22**:1007–18.
3 **Estenne M**, Maurer JR, Boehler A, *et al*. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. *J Heart Lung Transplant* 2002;**21**:297–310.
4 **Estenne M**, Hertz MI. Bronchiolitis obliterans after human lung transplantation. *Am J Respir Crit Care Med* 2002;**166**:440–4.
5 **Luckraz H**, Goddard M, McNeil K, *et al*. Microvascular changes in small airways predispose to obliterative bronchiolitis after lung transplantation. *J Heart Lung Transplant* 2004;**23**:527–31.
6 **Boehler A**, Kesten S, Weder W, *et al*. Bronchiolitis obliterans after lung transplantation: a review. *Chest* 1998;**114**:1411–26.
7 **Pomerance A**, Madden B, Burke MM, *et al*. Transbronchial biopsy in heart and lung transplantation: clinicopathologic correlations. *J Heart Lung Transplant* 1995;**14**:761–73.
8 **Chamberlain D**, Maurer J, Chaparro C, *et al*. Evaluation of transbronchial lung biopsy specimens in the diagnosis of bronchiolitis obliterans after lung transplantation. *J Heart Lung Transplant* 1994;**13**:963–71.
9 **Cooper JD**, Billingham M, Egan T, *et al*. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. *J Heart Lung Transplant* 1993;**12**:713–6.
10 **Worthy SA**, Park CS, Kim JS, *et al*. Bronchiolitis obliterans after lung transplantation: high-resolution CT findings in 15 patients. *AJR Am J Roentgenol* 1997;**169**:673–7.
11 **Leung AN**, Fisher K, Valentine V, *et al*. Bronchiolitis obliterans after lung transplantation: detection using expiratory HRCT. *Chest* 1998;**113**:365–70.
12 **Lee ES**, Gotway MB, Reddy GP, *et al*. Early bronchiolitis obliterans following lung transplantation: accuracy of expiratory thin-section CT for diagnosis. *Radiology* 2000;**216**:472–7.
13 **Siegel MJ**, Bhalla S, Gutierrez FR, *et al*. Post-lung transplantation bronchiolitis obliterans syndrome: usefulness of expiratory thin-section CT for diagnosis. *Radiology* 2001;**220**:455–62.
14 **Bankier AA**, Van Muylem A, Knoop C, *et al*. Bronchiolitis obliterans syndrome in heart-lung transplant recipients: diagnosis with expiratory CT. *Radiology* 2001;**218**:533–9.
15 **de Jong PA**, Ottink MD, Robben SG, *et al*. Computed tomography assessment of pulmonary disease in children with cystic fibrosis: various scoring system comparisons and bronchial and arterial measurements. *Radiology* 2004;**231**:434–9.
16 **Bankier AA**, Van Muylem A, Scillia P, *et al*. Air trapping in heart-lung transplant recipients: variability of anatomic distribution and extent at sequential expiratory thin-section CT. *Radiology* 2003;**229**:737–42.
17 **Konen E**, Gutierrez C, Chaparro C, *et al*. Bronchiolitis obliterans syndrome in lung transplant recipients: can thin-section CT findings predict disease before its clinical appearance? *Radiology* 2004;**231**:467–73.
18 **American Thoracic Society**. Standardization of spirometry, 1994 update. *Am J Respir Crit Care Med* 1995;**152**:1107–36.
19 **Brody AS**. Early morphologic changes in the lungs of asymptomatic infants and young children with cystic fibrosis. *J Pediatr* 2004;**144**:145–6.
20 **Brody AS**, Klein JS, Molina PL, *et al*. High-resolution computed tomography in young patients with cystic fibrosis: distribution of normalities and correlation with pulmonary function tests. *J Pediatr* 2004;**145**:32–8.
21 **Coxson HO**, Mayo JR, Behzad H, *et al*. Measurement of lung expansion with computed tomography and comparison with quantitative histology. *J Appl Physiol* 1995;**79**:1525–30.
22 **Coxson HO**, Rogers RM, Whittall KP, *et al*. A quantification of the lung surface area in emphysema using computed tomography. *Am J Respir Crit Care Med* 1999;**159**:851–6.
23 **Nakano Y**, Muro S, Sakai H, *et al*. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. *Am J Respir Crit Care Med* 2000;**162**:1102–8.
24 **Nakano Y**, Whittall KP, Kalloger SE, *et al*. Development and validation of human airway analysis algorithm using multidetector row CT. *Proc SPIE* 2002;**4683**:460–9.
25 **Hachem RR**, Chakinala MM, Yusen RD, *et al*. The predictive value of bronchiolitis obliterans syndrome stage 0-p. *Am J Respir Crit Care Med* 2004;**169**:468–72.

LUNG ALERT

No benefit from using pulmonary artery catheters to guide treatment of acute lung injury

▲ National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. *N Engl J Med* 2006;**354**:2213–24

Acute lung injury (ALI) is a prevalent and devastating condition in the intensive care unit. Although pulmonary artery catheters (PAC) provide clinicians with important data about a patient's haemodynamic status, doubts about their clinical benefit and worries about safety have raised questions about their usefulness. This study was designed to address this issue, with 1000 patients recruited in 20 North American centres. Patients were recruited after being diagnosed with ALI and were managed haemodynamically according to a standardised management protocol. 513 patients were randomised to have a PAC and 487 to have a standard central venous catheter (CVC).

Both the PAC and CVC groups had similar rates of death during the first 60 days (27.4% and 26.3% respectively, $p = 0.69$). Mean (SE) ventilator-free days were also similar (13.2 (0.5) and 13.5 (0.5), $p = 0.58$), as were the number of days not spent in the intensive care unit up to day 28 (12.0 (0.4) and 12.5 (0.5), $p = 0.40$). Using a PAC did not seem to reduce the incidence or the duration of organ failure or support in comparison with the CVC group. Although adverse events related to insertion of the catheters were uncommon, the PAC group had a higher number of complications than the CVC group (100 *v* 41), with the predominant complication being arrhythmia.

This study shows that using a PAC to guide treatment for ALI does not improve survival or organ function and is associated with more complications than CVC guided treatment.

J T C Yen
Specialist Registrar in Anaesthetics, Barnet General Hospital, London, UK; jtcyen@hotmail.com